SCHEMBL12366242

SCHEMBL12366242

COC(=O)c1ccc2c(c1)C(c1cccc(C)c1F)=CC(C)O2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IL2 P60568 2/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
PDK2 Q15119 2/20 0.37
RAB9A P51151 6/20 0.36
NPC1 O15118 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALOX5 P09917 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
MAPT P10636 5/20 0.35
POLB P06746 1/20 0.34
MCL1 Q07820 1/20 0.34
NOTUM Q6P988 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
ALDH1A1 P00352 1/20 0.34
RXFP1 Q9HBX9 1/20 0.33
MAPK14 Q16539 1/20 0.33
LMNA P02545 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12366136 0.90 RAB9A (0.41) IL2MEN1KMT2APDK2RAB9A
SCHEMBL12365205 0.89 MEN1 (0.43) MEN1KMT2APDK2RAB9ANPC1
SCHEMBL12389145 0.88 MEN1 (0.37) MEN1KMT2APDK2RAB9ANPC1
SCHEMBL12366140 0.88 KLKB1 (0.40) MEN1KMT2APDK2RAB9ANPC1
SCHEMBL12366277 0.87 TDP1 (0.39) MEN1KMT2AMAPTPOLBL3MBTL1
SCHEMBL12366211 0.86 IL2 (0.41) IL2MEN1KMT2APDK2RAB9A
SCHEMBL12365856 0.85 NPC1 (0.45) IL2MEN1KMT2APDK2RAB9A
SCHEMBL12366248 0.83 MAPK14 (0.40) IL2MEN1KMT2ARAB9ANPC1
SCHEMBL12366263 0.83 PARP1 (0.40) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL12389987 0.83 RAB9A (0.37) IL2MEN1KMT2APDK2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E IL2 3378/4885MEN1 4480/4885KMT2A 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.